Table 1. Demographics of children and adolescents aged 0–19 years tested for SARS-CoV-2 spike and nucleocapsid antibodies while undergoing an anesthetic procedure in a PAEDS hospital, between June 1 and August 31, 2022, in Australia.

	Number of samples (n)	Percentage of total (n/2046) (%)
Total population	2046
Jurisdictiona:
Australian Capital Territory	21	1.0
New South Wales	497	24.3
Northern Territory	108	5.3
Queensland	349	17.1
South Australia	382	18.7
Tasmania	14	0.7
Victoria	393	19.2
Western Australia	282	13.8
Age
0–5 months	62	3.0
6–11 months	80	3.9
1–4 years	673	32.9
5–11 years	696	34.0
12–15 years	397	19.4
16–19 years	138	6.7
Vaccination status
unvaccinated	1179	57.6
1 dose	124	6.1
2 or more dosesb	737	36.0
Unknown	6	0.3
Resident by Area of Remoteness Index (ARIA)
Major city	1495	73.1
Regional	499	24.4
Remote	52	2.5
Socio-economic status of area of residence (SEIFA, using IRSD c )
First (least advantaged)	368	18.0
Second	315	15.4
Third	438	21.4
Fourth	465	22.7
Fifth (most advantaged)	460	22.5
Sex
Male	1172	57.3
Female	872	42.6
Other	2	0.1
Aboriginal and Torres Strait Islander status
Aboriginal or Torres Strait Islander	177	8.7
Non-Indigenous	1869	91.3
Pre-existing medical condition
Present	728	35.6
None	1315	64.3
Unknown	3	0.1
Reported history of past infection d
Yes	1014	49.6
Vaccinated	456	22.3
Unvaccinated	554	27.1
Unknown	4	0.2
None	1019	49.8
Vaccinated	399	19.5
Unvaccinated	618	30.2
Unknown	2	0.1
Unknown	13	0.6

^aJurisdiction determined by resident postcode

^b680 participants received 2 doses, and 57 participants received 3 doses

^cIRSD: Index of Relative Socio-economic Disadvantage

^dparent/participant reported infection.